CD8 Polyclonal Antibody bs-0648R from Bioss Inc.

Product Specs
ItemCD8 Polyclonal Antibody
CompanyBioss Inc.
Price $375.00Supplier Page View Company Product Page
Catalog Numberbs-0648R
Molecular Weight27kDa
ImmunogenKLH conjugated peptide, mouse CD8
ApplicationsIF(IHC-F), WB, ELISA, FCM, IHC-P, IHC-F, IF(IHC-P), IF(IHC-F), IF(ICC), WB, IHC-F, IF(ICC), IHC, IHC-P, FCM, IF
Conjugate/TagUnconjugated
Antibody TypePrimary Antibody
ReactivityHuman, Mouse, Rat, Mouse, Human
IsotypeIgG
ClonalityPolyclonal
Format0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol
Quantity100ul, 20uL
TargetCD8
HostRabbit
Concentration1ug/ul
NCBI Gene AliasesLy-2, Ly-B, Lyt-2, Ly-35
NCBI Full Gene NameCD8 subunit alpha
Tissuelymph nodes, Osteotomised femora, tumor tissue, tumor, Other, liver, Kidney

Questions and Answers

Can this antibody be used for immunohistochemistry in mouse models?

Yes, the CD8 Polyclonal Antibody has been utilized in immunohistochemistry for mouse tissues, as demonstrated in studies where it was employed to analyze T-cell infiltration in various models, including those related to cancer and bone healing (, ).

What specific role does this antibody play in studies involving T cells?

The CD8 Polyclonal Antibody identifies cytotoxic T cells, which are crucial for T-cell mediated killing. It has been shown to be effective in assessing T-cell populations in various contexts, including tumor microenvironments and immune responses in transplantation models (, ).

Is this antibody effective in detecting CD8+ T cells in cancer research?

Yes, the CD8 Polyclonal Antibody has been cited in multiple studies focusing on cancer, where it was used to evaluate CD8+ T cell infiltration in tumor tissues, contributing to the understanding of immune responses in K-ras-driven cancers and other malignancies (, ).

What species does this antibody react with, and is it suitable for various experimental models?

The CD8 Polyclonal Antibody is reactive with mouse, human, and rat tissues, making it suitable for a wide range of experimental models, including those involving murine systems and human-derived samples (, ).

Bioss Inc.

300 Tradecenter Drive

Suite 4610

Woburn, MA 01801

United States

Phone: 800.501.7654 (Toll free)
Phone: +1.781.569.5821 (International)

Email: info@biossusa.com
orders@biossusa.com
support@biossusa.com
sales@biossusa.com

Company Profile

Website: www.biossusa.com

(1) AZD4635 Targets cAMP/CREB Axis to Salvage PARPi-Induced Immune Evasion and Enhance Antitumor Efficacy in Ovarian CancerPharmaceuticsFebruary 19, 2026Botao Pan, Xiujuan Yang, Xuanji Wang, Jiahao Fang, Qingqing Liu, Ning Zou, Chenglai Xia, Huiling Shangpurchased from Cell Signaling Technology (CST; Danvers, MA, USA). Antibodies specific to Cd8 (Cat. No. bs-0648R), Cd4 (Cat. No. bs-0647R), and Foxp3 (Cat. No. bs-0269R) were purchased from Beijing Bioss Biotechnology

(2) NGO ameliorates psoriasis by modulating mitochondrial function and suppressing pSTAT3–IL-17–expressing CD8+ TRM cellsJournal of NanobiotechnologyJanuary 16, 2026Tae Ho Kim, Chae Rim Lee, Kyoung Min Choi, Soon Won Choi, Seon-Yeong Lee, A. Ram Lee, Jung Won Choi, Young Mi Moon, Joonhyuck Park, Haeyoun Choi, et al.were incubated overnight (18 h) at 4 °C with the following primary monoclonal antibodies: anti-CD8 (BS-0648R; Bioss < Bioss Antibodies, Woburn, MA, USA), anti-IL-17 (ab79056; Abcam), and anti-pSTAT3 (Y705, ab76315;

(3) Histone lactylation drives METTL3 upregulation-mediated RNA m6A modification of CCT2 to hinder CD8+ T cell survival in gastric cancerCellular and Molecular Life SciencesNovember 25, 2025Zhenyuan Qian, Xufan Cai, Fang Wu, Zaiyuan Ye, Jianzhang Wuimmobilizing with 5% skim milk, the slices were kept overnight at 4 ℃ with primary antibodies against CD8 (bs-0648R, Bioss, China), METTL3 (HA720002, HUABIO, China), CCT2 (R26528, ZenBio, China), and Ki67 (HA721115,

(4) Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl-2/Bax PathwayCancer MedJune 11, 2025Xiaowei Li, Dengxiong Hua, Daoyan Wu, Wei Hong, Yingqian Kang, Lei Tang, Qin Yang, Xinxin Wang, Boyan Li, Renmin Li, et al.The tumor tissue sections were incubated with anti‐CD4 (Cat#11‐0040‐82; Invitrogen), anti‐CD8 (Cat#bs‐0648R; Bioss), anti‐Bax (Cat#50599‐2‐IG; Proteintech) and anti‐Ki‐67 (Cat#28074‐1‐AP; Proteintech) antibodies

(5) Ce6-GFFY is a novel photosensitizer for colorectal cancer therapyGenes & DiseasesMarch 1, 2025Wei Qiao, Shuxin Li, Linna Luo, Meiling Chen, Xiaobin Zheng, Jiacong Ye, Zhaohui Liang, Qiaoli Wang, Ting Hu, Ling Zhou, et al.anti-Gr-1 (#108401, BioLegend), mouse anti-Cytokeratin Pan (#ab7753, Abcam), and rabbit anti-CD8 (#bs-0648R, Bioss). The sections were washed with cold PBS and incubated with the mixture of two secondary antibodies

(6) Ginger-Derived Exosome-Like Nanoparticles Loaded With Indocyanine Green Enhances Phototherapy Efficacy for Breast CancerInternational Journal of NanomedicineJanuary 30, 2025Zhaoming Guo, Guqing Li, Lanjun Shen, Jiawei Pan, Danni Dou, Yuwei Gong, Wanwan Shi, Yuhua Sun, Yi Zhang, Kun Ma, et al.Proteintech, 28083-1-AP), IFN gamma rabbit pAb (1:500, Bioss, bs-0480R), and CD8 Rabbit pAb (1:500, Bioss, bs-0648R). Detection of IL-6 Expression in Mouse Tumor Tissues by ELISA Tumor tissues were extracted from each

(7) Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunityNat CommunJanuary 13, 2025Mingjiong Zhang, Jiahua Cui, Haoyan Chen, Yifan Cheng, Qiaoyu Chen, Feng Zong, Xiao Lu, Lang Qin, Yu Han, Xingwang Kuai, et al.#27309-1-AP) and SOAT2 (1:20, Proteintech, #21852-1-AP), FOXP3 (1:100, Abcam, #ab215206), CD8 (1:50, Bioss, #bs-0648R), respectively. All of the staining was assessed by pathologists blinded to the origination of the samples

(8) Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicityNeoplasiaJanuary 1, 2025Ruichen Huang, Qiao Zhou, Jiajun Liu, Yang Xia, Yang Jiao, Bi Zhao, Tangtao Feng, Haosu Zhou, Xiuyan Song, Hao Qin, et al.included recombinant anti-CD4 antibody (Bioss, bs-0766R, 1:4000) and anti-mouse CD8 antibody (Bioss, bs-0648R, 1:2000). The secondary antibody was Goat Anti-Rabbit IgG H&L (HRP) (Abcam, ab205718, 1:5000), and the

(9) Stimulator of interferon gene facilitates recruitment of effector CD8 T cells that drive neurofibromatosis type 1 nerve tumor initiation and maintenanceScience advancesOctober 18, 2024Pundavela J, Dinglasan SA, Touvron M, Hummel SA, Hu L, Rizvi TA, Choi K, Hildeman DA, Ratner N.anti-CD4 rabbit polyclonal antibody (BS-0647R, Bioss Antibodies), anti-CD8A rabbit polyclonal antibody (BS-0648R, Bioss Antibodies), XCR1 (D2F8T) rabbit mAb (no. 44665S, Cell Signaling Technology), CD103/INGAE (integrin

(10) A pan-KRAS degrader for the treatment of KRAS-mutant cancersCell discoveryJune 28, 2024Yang J, Wang QL, Wang GN, Ye JC, Li ZQ, Wang JY, Liang ZH, Li SX, Sun C, Liao WT, et al.anti-Gr-1 (#108401, BioLegend), mouse anti-Cytokeratin Pan (#ab7753, Abcam), and rabbit anti-CD8 (#bs-0648R, Bioss). The slides were washed with cold PBS and incubated with a mixture of two secondary antibodies

(11) PGRN inhibits CD8+T cell recruitment and promotes breast cancer progression by up-regulating ICAM-1 on TAMCancer Immunol ImmunotherMarch 30, 2024Ting Zhou, Husun Qian, Dian Zhang, Wenli Fang, MengLi Yao, He Shi, Tingmei Chen, Chengsen Chai, Bianqin Guo(Proteintech, 18,704–1-AP, 1:200), Arg1 (Abcam, ab96183, 1:100), iNOS (Abcam, ab178945, 1:200), CD8 (Bioss, bs0648R, 1:100), aSMA (Cell Signaling Technology, 19,245, 1:200); Ki67 (Cell Signaling Technology, 12,075, 1:100);

(12) Engineering Proteus mirabilis improves antitumor efficacy via enhancing cytotoxic T cell responsesMol Ther OncolMarch 21, 2024Zhang H, Luo Y, Zhao X, Liu X.peroxidase-linked secondary antibody for 50 min at room temperature. The primary antibodies were CD8 (bs-0648R, Bioss Antibodies, 1:200), CD4 (bs-0647R, Bioss Antibodies, 1:200), and PD-L1 (bs-1103R, Bioss Antibodies,

(13) Overcoming the On-Target Toxicity in Antibody-Mediated Therapies via an Indirect Active Targeting StrategyAdvanced science (Weinheim, Baden-Wurttemberg, Germany)March 1, 2023Tang Z, Wang X, Tang M, Wu J, Zhang J, Liu X, Gao F, Fu Y, Tang P, Li C.anti‐CD45/AF488 conjugated antibody (bsm‐30095M‐AF488), rabbit anti‐CD8/AF594 conjugated antibody (bs‐0648R‐AF594), and HRP‐labeled goat anti‐rabbit IgG (bs‐40295G‐HRP) were purchased from Bioss Biotechnology

(14) Water-responsive gel extends drug retention and facilitates skin penetration for curcumin topical delivery against psoriasisAsian journal of pharmaceutical sciencesMarch 1, 2023Yao Q, Zhai YY, He Z, Wang Q, Sun L, Sun T, Lv L, Li Y, Yang J, Lv D, et al.donkey anti-rabbit IgG H&L (Alexa Fluor® 647) were obtained from Abcam (MA, US). The anti-CD4 (bs-0647R) and anti-CD8 (bs-0648R) were purchased from BIOSS company (Beijing, China). The anti-cytokeratin 10 (CK 10, AF0197), anti-IL-6

(15) LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancerBMC medical genomicsJanuary 18, 2023Zhu X, You S, Du X, Song K, Lv T, Zhao H, Yao Q.were then incubated with anti-LRRC15 (NBP1-93,556, Novus), anti-PDPN (bs-1048R, Bioss) and anti-CD8 (bs-0648R, Bioss) antibodies. PBS buffer was used as negative control instead of primary antibody. This was followed

(16) Altered early immune response after fracture and traumatic brain injuryFrontiers in immunologyJanuary 1, 2023Haffner-Luntzer M, Weber B, Morioka K, Lackner I, Fischer V, Bahney C, Ignatius A, Kalbitz M, Marcucio R, Miclau T.USA), goat anti-mouse CXCL10 (1:50; #AF-466-NA, R&D systems), rabbit anti-mouse CD8 (1:500, Bioss #bs-0648R). As secondary antibodies, goat-anti rabbit IgG-biotin (1:200; #B2770, Life Technologies, Carlsbad,

(17) Targeting the STAT5A/IDO1 axis overcomes radioresistance and reverses the immunosuppressive tumor microenvironment in NSCLCInternational journal of oncologyJanuary 1, 2023Yang Y, Zheng X, Ni P, Li D, Dan Q, Wang X, Wang Y, Sun Y, Liu K, Dong Z, et al.anti-mouse IDO1 (1:1,000; cat. no. 122402; BioLegend, Inc.); rabbit anti-mouse CD8 (1:200; cat. no. bs-0648R; Bioss antibodies, Inc.), rabbit anti-STAT5A (1:200; cat. no. ab32043; Abcam, Inc.), rabbit anti-Ki67

(18) Safety and Efficacy of Intraventricular Immunovirotherapy with Oncolytic HSV-1 for CNS CancersClinical Cancer ResearchDecember 15, 2022Kyung-Don Kang, Joshua D. Bernstock, Stacie K. Totsch, Sam E. Gary, Abbey Rocco, Li Nan, Rong Li, Tina Etminan, Xiaosi Han, Elizabeth A. Beierle, et al.microtome. Slides were incubated overnight at 4°C with primary antibodies including CD8 (Bioss Cat# bs-0648R, RRID:AB_10857537), HSV-1 (Abcam Cat# ab20536, RRID:AB_732857), gD (Santa Cruz Biotechnology Cat# sc-69802,

(19) Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancerJournal of advanced researchSeptember 1, 2022Glorieux C, Xia X, You X, Wang Z, Han Y, Yang J, Noppe G, Meester C, Ling J, Robert A, et al.as previously described [8]. Primary antibodies were rabbit anti-mouse CD8 (Bioss, Woburn, MA, USA; #bs-0648R), rabbit anti-human CD8 (ZSGB-Bio, Beijing, China; #ZA-0508), rabbit anti-human CD4 (Abcam; #ab133616),

(20) Combined treatment with epigenetic agents enhances anti-tumor activity of MAGE-D4 peptide-specific T cells by upregulating the MAGE-D4 expression in gliomaFrontiers in OncologyAugust 3, 2022Shui-Qing Bi et al.Immunohistochemistry (IHC) Immunochemistry was conducted to detect expressions of CD8 on tissue sections. CD8 antibody (BS-0648R, Bioss, China) was used as the primary antibody. An isotype-matched antibody was used as a control.

Be the First to Write a Review!

WB

CD8 Polyclonal Antibody

WB

WB

IHC-P

CD8 Polyclonal Antibody from Bioss Inc.

Description

Questions and Answers

Bioss Inc.

Citations (71)

Reviews

CD8 Polyclonal Antibody from Bioss Inc.

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map